Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 21 2022 - 05:21PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December 2022
Commission File Number: 001-38547
Autolus Therapeutics plc
(Translation of registrant’s name into
English)
The MediaWorks
191 Wood Lane
London W12 7FP
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form
40-F
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted
by Regulation S-T Rule
101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted
by Regulation S-T Rule
101(b)(7): ☐
INCORPORATION BY REFERENCE
The information contained in this Report, including Exhibit 99.1 of
this Report, shall be deemed to be incorporated by reference into
the registration statements on Form S-8 (File No. 333-226457), Form F-3 (File No. 333-258556), Form F-3 (File No. 333-264304), and Form
F-3 (File No. 333-264650) of Autolus
Therapeutics plc (the “Company”) and any related prospectuses, as
such registration statements and prospectuses may be amended from
time to time, and to be a part thereof from the date on which this
Report is filed, to the extent not superseded by documents or
reports subsequently furnished.
Press Release
On December 21, 2022, the Company issued a press release, a
copy of which is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Autolus Therapeutics plc |
|
|
|
|
Date: December 21, 2022 |
|
|
|
By: |
|
/s/ Christian Itin
|
|
|
|
|
|
|
Name |
|
Christian Itin, Ph.D. |
|
|
|
|
|
|
Title: |
|
Chief Executive Officer |
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From May 2023 to May 2023
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From May 2022 to May 2023